Alyeska Investment Group
LUMO

Alyeska Investment Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Alyeska Investment Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27,529
Closed -$1.8M – 542
2018
Q1 		$1.8M Sell
27,529
-249
-0.9% -$17.6K 0.01% 354
2017
Q4 		$2.03M Buy
+27,778
New +$2.3M 0.02% 337

Other funds holding LUMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alyeska Investment Group's LUMO Position: Q2 2018 in Review

Alyeska Investment Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 27,529 shares — an estimated $1.8M sold.

Alyeska Investment Group first reported a position in LUMO in Q4 2017 and held it in 2 quarters. The position peaked at $2.03M in Q4 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

  • Alyeska Investment Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 27,529 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $1.8M.
  • Alyeska Investment Group first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Alyeska Investment Group's Lumos Pharma, Inc. Common Stock position peaked at $2.03M in Q4 2017.
  • 106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.